Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Inclusion Criteria: * PHASE I PORTION ELIGIBILITY CRITERIA: * Patients must have BRAF\^V600 mutant metastatic cancer irrespective of the histology or prior therapy; BRAF\^V600 mutant status must be documented by a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory; use of an Food and Drug Administration (FDA)-approved test is preferred although other BRAF tests at a CLIA-certified laboratory may also be accepted * Patients must have locally advanced unresectable stage IIIC or metastatic stage IV cancer with either progression to prior therapy or a newly diagnosed cancer that does not have an available treatment with curative intent * Patients must have a complete physical examination and medical history within 28 days prior to registration * Patients must have measurable or non-measurable disease; all measurable lesions must be assessed (by physical examination, computed tomography \[CT\], or magnetic resonance imaging \[MRI\] scan) within 28 days prior to registration; tests to assess non-measurable disease must be performed within 42 days prior to registration; all disease must be assessed and documented on the baseline tumor assessment form (Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1) * All patients must undergo a CT or MRI of the brain within 42 days prior to registration; patients with asymptomatic brain metastases or previously treated brain metastases that are stable (i.e. not requiring corticosteroids) at the time of registration …